Search

Displaying results 3831 - 3840 of 5419 in total
  1. Drug

    TDI-01

    go.drugbank.com/drugs/DB19450
    Investigational

    TDI-01 is a small molecule is being developed by Beijing Tide Pharmaceutical.

  2. Drug

    Plasmin (Human)

    go.drugbank.com/drugs/DB22676
    Investigational

    The enzyme plasmin causes clot lysis by cleaving fibrin, a clot component.[L53453]

  3. Drug

    CHO Cells Recombinant Vaccine

    go.drugbank.com/drugs/DB15893
    Experimental

    The vaccine candidate is sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is undergoing phase I clinical trials to evaluate safety and tolerability. … This vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758].

  4. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group

  5. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

  6. Drug

    Sitafloxacin

    go.drugbank.com/drugs/DB13261
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components...

  8. Drug

    NPS-2143

    go.drugbank.com/drugs/DB05695
    Experimental

  9. Drug

    Flovagatran

    go.drugbank.com/drugs/DB05714
    Experimental

  10. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be...